The medication, called Rekovelle, was launched last year by Ferring, a privately held Swiss multinational pharmaceutical company, which in 2005 acquired Bio-Technology General (Israel) Ltd. (BTG).

It has been about a month since the last earnings report for B2Gold (BTG). Shares have lost about 11.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

B2Gold (BTG) is poised for a strong 2025 with anticipated production growth of 20-33%, driven by the Fekola and Goose projects. Despite a challenging 2024, BTG's low valuation and rising gold ...

B2Gold (BTG) closed the most recent trading day at $2.57, moving -0.77% from the previous trading session. This change lagged the S&P 500's 1.26% gain on the day. At the same time, the Dow added 0 ...

B2Gold Corp (Symbol: BTG) has been named as a Top 5 dividend paying metals and mining stock, according to Dividend Channel, which published its weekly ''DividendRank'' report. The report noted ...

SAO PAULO, Jan 16 (Reuters) - Brazilian lenders BTG Pactual, Bradesco and Santander Brasil are among those most exposed to debt of Americanas SA (AMER3.SA), opens new tab, analysts' estimates ...

Ferring on Thursday opened a new global manufacturing hub in Kuopio, Finland, to help produce drug substance for Adstiladrin, which was approved by the FDA in late 2022 as the first gene therapy ...

RELATED: Ferring's C. difficile drug overcomes skepticism to secure FDA committee nod C. diff. is a superbug that resists antibiotics and other medications. The disorder causes roughly 500,000 ...

Banco BTG Pactual SA, the biggest independent investment bank in Latin America, is close to announcing the acquisition of a wealth-management bank in New York as part of a global expansion ...